Compile Data Set for Download or QSAR
maximum 50k data
Found 194 with Last Name = 'cho' and Initial = 'jm'
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Seoul National University

Curated by ChEMBL
LigandPNGBDBM50103521(Actos | CHEBI:8228 | Duetact | Pioglitazone | US10...)
Affinity DataKi:  62nMAssay Description:Binding affinity to PPARgamma (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Seoul National University

Curated by ChEMBL
LigandPNGBDBM50012957(1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfon...)
Affinity DataKi:  660nMAssay Description:Binding affinity to PPARgamma (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Seoul National University

Curated by ChEMBL
LigandPNGBDBM50508713(CHEMBL4555353)
Affinity DataKi:  1.49E+4nMAssay Description:Binding affinity to PPARgamma (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Seoul National University

Curated by ChEMBL
LigandPNGBDBM50508712(CHEMBL4453254)
Affinity DataKi:  1.81E+4nMAssay Description:Binding affinity to PPARgamma (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Seoul National University

Curated by ChEMBL
LigandPNGBDBM50508711(CHEBI:5092 | Flidersiachromone)
Affinity DataKi:  5.40E+4nMAssay Description:Binding affinity to PPARgamma (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein phosphatase non-receptor type 1 [1-301](Homo sapiens (Human))
Washington College

LigandPNGBDBM50076273((2R,3R)-2,3-Bis-[(E)-3-(3,4-dihydroxy-phenyl)-acry...)
Affinity DataKi:  1.40E+6nMAssay Description:Steady-state kinetic parameters were measured for PTP1B using p-nitrophenyl phosphate (pNPP, 0.5−40 mM) as the substrate in NMR buffer. The rat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein phosphatase non-receptor type 1 [1-301](Homo sapiens (Human))
Washington College

LigandPNGBDBM50327036((1R,3S,4S,5S)-3-[(E)-3-(3,4-Dihydroxy-phenyl)-acry...)
Affinity DataKi:  8.20E+6nMAssay Description:Steady-state kinetic parameters were measured for PTP1B using p-nitrophenyl phosphate (pNPP, 0.5−40 mM) as the substrate in NMR buffer. The rat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340036(1-(3-chloro-2,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340036(1-(3-chloro-2,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340036(1-(3-chloro-2,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340037(1-(2-chloro-3,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340037(1-(2-chloro-3,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340037(1-(2-chloro-3,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340031(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340031(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340031(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340033(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340033(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340033(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340032(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340032(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340032(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340039(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340030(1-(2-chloro-6-fluoro-phenyl)-3-{3-fluoro-4- [7-(5-...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340039(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340030(1-(2-chloro-6-fluoro-phenyl)-3-{3-fluoro-4- [7-(5-...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340039(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340030(1-(2-chloro-6-fluoro-phenyl)-3-{3-fluoro-4- [7-(5-...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50365602(CHEMBL1957949)
Affinity DataIC50:  1nMAssay Description:Inhibition of GSK3-betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340029(1-(2,6-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340029(1-(2,6-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386918(CHEMBL2048663)
Affinity DataIC50:  1nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340029(1-(2,6-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386940(CHEMBL2048685)
Affinity DataIC50:  2nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386939(CHEMBL2048684)
Affinity DataIC50:  2nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386935(CHEMBL2048680)
Affinity DataIC50:  2nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386915(CHEMBL2048660)
Affinity DataIC50:  2nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386925(CHEMBL2048670)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386931(CHEMBL2048676)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386932(CHEMBL2048677)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386933(CHEMBL2048678)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386937(CHEMBL2048682)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50365609(CHEMBL1957956)
Affinity DataIC50:  3nMAssay Description:Inhibition of GSK3-betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386936(CHEMBL2048681)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386917(CHEMBL2048662)
Affinity DataIC50:  3nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Crystalgenomics

Curated by ChEMBL
LigandPNGBDBM50386914(CHEMBL2048659)
Affinity DataIC50:  4nMAssay Description:Inhibition of human GSK3beta using phospho-CREB as substrate by beta counting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340038(1-(4-chloro-2,6-difluoro-phenyl)-3-{3- fluoro-4-[7...)
Affinity DataIC50:  4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340038(1-(4-chloro-2,6-difluoro-phenyl)-3-{3- fluoro-4-[7...)
Affinity DataIC50:  4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340038(1-(4-chloro-2,6-difluoro-phenyl)-3-{3- fluoro-4-[7...)
Affinity DataIC50:  4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340035(1-(4-cyano-3-fluorophenyl)-3-(3-fluoro-4- (7-(5-me...)
Affinity DataIC50:  5nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 194 total ) | Next | Last >>
Jump to: